Last reviewed · How we verify
Fabry's disease
Approved treatments
- Replagal · National Institute of Neurological Disorders and Stroke (NINDS)
- Elfabrio · Chiesi Farmaceutici S.P.A
Elfabrio works by reducing the accumulation of a specific lipid in the body. - Fabrazyme · Sanofi
Fabrazyme works by replacing the deficient enzyme alpha-Gal A to break down and remove toxic globotriaosylceramide. - ELFABRIO · CHIESI FARMACEUTICI SPA
- Replagal
- Galafold · Amicus Therap Us
Galafold stabilizes the alpha-galactosidase A enzyme to treat Fabry's disease. - agalsidase · Amicus Therapeutics
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Fabry's disease patent landscape — cliff calendar, originator estates, attackable patents
- Fabry's disease treatment landscape brief
- Fabry's disease treatment updates RSS
Frequently asked questions about Fabry's disease
What drugs treat Fabry's disease?
Tracked treatments include Replagal, Elfabrio, Fabrazyme, ELFABRIO, Galafold, agalsidase.
What is the treatment for Fabry's disease?
Standard treatment for Fabry's disease includes Replagal, Elfabrio, Fabrazyme, ELFABRIO, Galafold. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Fabry's disease patent cliff · Fabry's disease CI report
- Treatment: Replagal · National Institute of Neurological Disorders and Stroke (NINDS)
- Treatment: Elfabrio · Chiesi Farmaceutici S.P.A
- Treatment: Fabrazyme · Sanofi
- Treatment: ELFABRIO · CHIESI FARMACEUTICI SPA
- Treatment: Replagal
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing